Merit Medical Systems IncMMSI

Merit Medical Systems Inc filed its 10-Q on 30 April 2026, showing revenue of $381.9 million for the quarter ended 31 March 2026, net income attributable to parent of $41.0 million, and diluted earnings per share of $0.68. The same filing reports operating income of $44.2 million, cash and cash equivalents of $488.1 million, and a $22.7 million increase in net inventory to $352.4 million. Operating cash flow for the quarter was $40.7 million, while capital expenditure on property, plant, and equipment totalled $16.0 million. Weighted average diluted shares outstanding stood at 60.0 million. (source: Official SEC EDGAR, https://www.sec.gov/Archives/edgar/data/856982/000085698226000025/mmsi-20260331x10q.htm)

Merit Medical makes devices and systems for cardiac, oncology, renal, vascular, and endoscopic procedures, and sells branded products such as StatSeal and WoundSeal after acquiring the Biolife line. The company’s procedural-solutions pages and inflation-device portfolio position it as a market leader in embolization and radial-access technologies, with product images and family pages hosted on the corporate site. (source: Official product/news rail, https://www.merit.com/products/solutions/; https://www.merit.com/solutions/inflation-devices/)

The 11-K filed on 26 June 2026 confirms Massachusetts Financial Services Mid Cap Value Fund among the largest common-stock holders, but provides no evidence of a fresh capital raise or transformative acquisition during the period. Form 4 filings in May and June 2026 show routine insider share transactions rather than blockbuster purchases or sales, indicating no sudden change in executive conviction. (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/856982/000085698226000034/mmsi-20251231x11k.htm; https://www.sec.gov/Archives/edgar/data/856982/000170814426000004/xslF345X06/form4-05212026_010507.xml; https://www.sec.gov/Archives/edgar/data/856982/000183695826000006/xslF345X06/form4-06172026_010652.xml)

For investors who like to map the story to a chart, Merit Medical’s shares trade on the Nasdaq under the ticker MMSI; the company’s SEC filings, insider trades, and product pages are the primary rails for gauging operating reality rather than macro noise. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=856982)

What remains unproven is any step-change in product cadence or regulatory approvals beyond the existing portfolio. The company’s conflict-minerals report for 2026 is publicly posted, but it does not disclose new patent grants or major clinical milestones in the latest filings. If Merit Medical is to justify its valuation uplift, it will need to show either accelerating organic growth in radial access or embolization, or a tangible uptick in operating cash conversion beyond the $40.7 million recorded in the last quarter. The next 10-Q will be the first test of whether inventory expansion translates into cash generation or simply weighs on working capital. (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/856982/000085698226000032/mmsi-20260529xsd.htm)